Targeting VISTA has shown potential in preclinical models of GBM, where VISTA blockade enhanced T-cell responses and improved the efficacy of combination therapies with other immune checkpoint inhibitors (such as PD-1/PD-L1 inhibitors) (Ghosh et al., 2023; Petterson et al., 2023). This evidence concerns the gene VSIR and glioblastoma.